The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1054
June 4, 1999
View Complete Issue         Table of Contents 2019 
Interferon Plus Ribavirin for Chronic Hepatitis C
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Interferon Plus Ribavirin for Chronic Hepatitis C
June 4, 1999 (Issue: 1054)
Rebetron, a combination of injected recombinant interferon alfa-2b with oral ribavirin has been approved by the FDA for treatment of chronic hepatitis C virus infection.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Interferon Plus Ribavirin for Chronic Hepatitis C
Article code: 1054b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.